Trial Profile

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of LEVI-04 in Patients With Osteoarthritis of the Knee

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 22 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs LEVI 04 (Primary)
Indications Musculoskeletal pain
Focus Therapeutic Use
Sponsors Levicept

Most Recent Events

27 Oct 2025 According to Levicept media release, data from this trial were presented at the American College of Rheumatology's annual meeting, ACR Convergence 2025.
27 Oct 2025 Results published in the Media Release
27 Oct 2025 According to Levicept media release, new clinical data from this trial will be presented by Simon Westbrook, Founder and CSO of Levicept, at in a plenary presentation at the American College of Rheumatology's annual meeting, ACR Convergence 2025, in Chicago, Illinois.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com